Report initial Phase 1 results from the SURF301 oncology study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 19 Mar 2024
- Due
- 31 Dec 2024
- Delivered
- October 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“TYRA expects to submit initial results from its SURF301 Phase 1 portion for presentation at a scientific congress in the second half of 2024.”
What we found
Evidence strength A What the grades mean
The company reported interim clinical proof-of-concept data from the SURF301 study in October 2024, which falls within the second half of 2024.
-
A Tyra Biosciences, Inc. 10-K filed 2025-03-27
“In late October 2024, we reported interim data that in patients with FGFR3+ mUC who received doses ≥ 90 mg once daily (QD), 6 out of 11 (54.5%) patients achieved a confirmed partial response (PR).” ✓ confirmed on the page
Market reaction: the shares moved -7.6% against the S&P 500 over the three sessions around the disclosure (26 Mar 2025 to 31 Mar 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +1095 days
- 3 versions
-
Version 1 · original · stated 19 Mar 2024
Deadline 31 Dec 2024 (“in the second half of 2024”) · wording expected
-
Version 2 · stated 9 May 2024
Deadline 31 Dec 2024 (“second half of 2024”) · wording firm
“TYRA remains on track to report initial results from its SURF301 Phase 1 portion at a scientific congress in the second half of 2024.”
-
Version 3 · stated 4 Aug 2026
Deadline 31 Dec 2027 (“2027”) · wording expected
“Initial results from this study are expected in 2027.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- SURF301 Phase 1 clinical trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tyra Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-TYRA-002073 · Corrections policy